Patient Considerations for Front-line Systemic Immunotherapies in uHCC.

James J. Harding, MD, discusses how the initial findings from CheckMate 9DW inform the role of nivolumab plus ipilimumab (NIVO + IPI) in the first-line (1L) treatment landscape for unresectable hepatocellular carcinoma (uHCC), considering factors such as efficacy, safety, and patient characteristics (eg, age) when selecting between first-line systemic immunotherapy (IO) regimens.

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

EP: 4.Navigating Between Front-line Systemic Therapies in uHCC.

Now Viewing

EP: 5.Patient Considerations for Front-line Systemic Immunotherapies in uHCC.

Video content above is prompted by the following:

• Given initial findings from CheckMate 9DW, where do you see NIVO + IPI fitting into the 1L treatment landscape for uHCC? Thinking about efficacy vs safety, which factors (eg, age,…) would you consider when selecting between 1L systemic IO regimens?
  • Which patients would be best suited to receiving NIVO + IPI in 1L?

Recent Videos